RemeGen (9995) Stock Overview
A biopharmaceutical company, discovers, develops, produces and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
9995 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
RemeGen Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$95.60 |
| 52 Week High | HK$126.60 |
| 52 Week Low | HK$11.52 |
| Beta | 0.88 |
| 1 Month Change | -13.87% |
| 3 Month Change | 35.12% |
| 1 Year Change | 556.59% |
| 3 Year Change | 117.27% |
| 5 Year Change | n/a |
| Change since IPO | 36.96% |
Recent News & Updates
Recent updates
What RemeGen Co., Ltd.'s (HKG:9995) 32% Share Price Gain Is Not Telling You
Sep 18
Need To Know: Analysts Are Much More Bullish On RemeGen Co., Ltd. (HKG:9995) Revenues
Aug 27RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 26% But Its Business Is Yet to Catch Up
Jul 29RemeGen Co., Ltd.'s (HKG:9995) 28% Price Boost Is Out Of Tune With Revenues
Jun 10RemeGen (HKG:9995) Is Carrying A Fair Bit Of Debt
May 12RemeGen Co., Ltd.'s (HKG:9995) 68% Price Boost Is Out Of Tune With Revenues
Apr 21RemeGen Co., Ltd.'s (HKG:9995) Shares Bounce 33% But Its Business Still Trails The Industry
Mar 06The Market Doesn't Like What It Sees From RemeGen Co., Ltd.'s (HKG:9995) Revenues Yet As Shares Tumble 30%
Jan 12There's No Escaping RemeGen Co., Ltd.'s (HKG:9995) Muted Revenues Despite A 25% Share Price Rise
Nov 27Shareholder Returns
| 9995 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -10.0% | -15.1% | -1.1% |
| 1Y | 556.6% | 117.7% | 29.4% |
Return vs Industry: 9995 exceeded the Hong Kong Biotechs industry which returned 117.7% over the past year.
Return vs Market: 9995 exceeded the Hong Kong Market which returned 29.4% over the past year.
Price Volatility
| 9995 volatility | |
|---|---|
| 9995 Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in HK Market | 15.6% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 9995's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9995's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 3,070 | Jianmin Fang | www.remegen.com |
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus (SLE) an autoimmune disease, as well as Disitamab Vedotin (RC48) for use in the treatment of various cancers. It also develops products in various stages, including RC28, which is under phase III clinical trials for the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC88, which is in Phase II clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors; RC148, also in Phase II clinical trials for the treatment of Multiple Solid Tumors.
RemeGen Co., Ltd. Fundamentals Summary
| 9995 fundamental statistics | |
|---|---|
| Market cap | HK$55.52b |
| Earnings (TTM) | -HK$1.24b |
| Revenue (TTM) | HK$2.26b |
Is 9995 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9995 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.07b |
| Cost of Revenue | CN¥351.00m |
| Gross Profit | CN¥1.72b |
| Other Expenses | CN¥2.86b |
| Earnings | -CN¥1.14b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 31, 2025
| Earnings per share (EPS) | -2.05 |
| Gross Margin | 83.07% |
| Net Profit Margin | -54.87% |
| Debt/Equity Ratio | 110.5% |
How did 9995 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/16 15:37 |
| End of Day Share Price | 2025/10/16 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RemeGen Co., Ltd. is covered by 34 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shun Kei Law | CCB International Securities Limited |
| Zhishun Siu | CCB International Securities Limited |
| Ziyu He | China International Capital Corporation Limited |